Acme Therapeutics

ONC-002 · Relapsed/refractory multiple myeloma

Phase 2bEnrollingOncologyWatch

Executive summary

Single-arm dose-expansion of acemyebrelin in r/r multiple myeloma. Enrolment is tracking 12% behind plan due to slow activation at two EU sites; mitigation underway with two new US sites in start-up.

Phase

Phase 2b

Stage

Enrolling

Health

Watch

Milestone timeline

Showing completed, in-progress, and at-risk milestones. Planned future milestones are omitted from the sponsor view.

Sep 15, 2024forecast end Jun 12, 2027

FPI
Oct 2, 2024
Complete
25% enrolment
Mar 10, 2025
Complete
50% enrolment
Jul 22, 2025
Complete
75% enrolment
Jan 15, 2026
In progress
LPI
May 30, 2026
At risk

Signed deliverables

Updated live as deliverables are signed.

Essential Documents
filed and signed
Audit Trail
green
CSR draft
not yet released to sponsor

Request an update

Ask for a status update, request a document, or submit a question. The study lead is notified and you’ll see the response in this portal.